◆英語タイトル:Ceapro Inc (CZO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012273
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月14日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Ceapro Inc (Ceapro) is a biotechnology company which focuses on the development of extraction technology for use in the production of extracts and active ingredients from oats and other renewable plant resources. These extracts find application in therapeutic products for both humans and animals and cosmeceutical and nutraceutical industries. The company’s portfolio include natural active ingredients comprising oat avenanthramides, oat oil, oat peptides, oat beta glucan, and lupin peptides; and veterinary products including oat shampoo, ear cleanser and dermal complex/conditioner. The company along with its subsidiaries operates mainly in the US, Germany, China, Canada and other countries. Ceapro is headquartered in Edmonton, Alberta, Canada.
Ceapro Inc (CZO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Ceapro Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Ceapro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ceapro Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Ceapro Expands Licensing Agreement with University of Alberta 10
Ceapro Enters into Licensing Agreement with University of Alberta 11
Symrise Enters Into Licensing Agreement With Ceapro 12
Equity Offering 13
Ceapro Raises USD3.3 Million in Second and Final Tranche of Private Placement of Units 13
Ceapro Raises USD4.4 Million in First Tranche of Brokered Private Placement of Units 15
Debt Offering 17
Ceapro Raises USD0.24 Million in Second Tranche of Private Placement of Debentures Due 2016 17
Ceapro Inc – Key Competitors 18
Ceapro Inc – Key Employees 19
Ceapro Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Nov 15, 2017: Ceapro Reports 2017 Third Quarter Business Update and Financial Results 21
Aug 18, 2017: Ceapro Reports 2017 Second Quarter Business Update and Financial Results 23
May 17, 2017: Ceapro Reports 2017 First Quarter Development Highlights and Financial Results 25
Apr 06, 2017: Ceapro Reports 2016 Financial Results and Provides Corporate Update 27
Nov 23, 2016: Ceapro Reports Third Quarter 2016 Financial and Operational Results 29
Aug 24, 2016: Ceapro Reports Second Quarter 2016 Financial and Operational Results 30
May 18, 2016: Ceapro Reports 2016 First Quarter Financial Results and Provides Corporate Update 31
Apr 14, 2016: Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company’s History 33
Legal and Regulatory 34
Feb 03, 2016: Ceapro Issued U.S. Patent for Enabling Pressurized Gas Expanded Technology 34
Government and Public Interest 35
Sep 21, 2016: Ceapro Awarded Research Grant from German-Canadian Centre for Innovation and Research 35
Other Significant Developments 36
Apr 18, 2016: Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Tables
Ceapro Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Ceapro Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Ceapro Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Ceapro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ceapro Expands Licensing Agreement with University of Alberta 10
Ceapro Enters into Licensing Agreement with University of Alberta 11
Symrise Enters Into Licensing Agreement With Ceapro 12
Ceapro Raises USD3.3 Million in Second and Final Tranche of Private Placement of Units 13
Ceapro Raises USD4.4 Million in First Tranche of Brokered Private Placement of Units 15
Ceapro Raises USD0.24 Million in Second Tranche of Private Placement of Debentures Due 2016 17
Ceapro Inc, Key Competitors 18
Ceapro Inc, Key Employees 19
Ceapro Inc, Subsidiaries 20